Abstract
Benefits of this report
- This report has evolved during the past 14 years, profiting from feedback
by numerous readers and experts.
- The most comprehensive and up-to-date one-stop source of information on
technical and commercial aspects of molecular diagnostics.
- Includes profiles of 283 companies, the largest number in any report on
this topic.
- 500 references, cited in the report are included in the bibliography.
- The text is supplemented by 89 tables and 15 figures.
Who should read this report?
- Chief executive officers of molecular diagnostic companies.
- Business development executives of pharmaceutical and biotechnology
companies.
- Executives of companies involved in developing integration of diagnosis
and treatment as well as those interested in personalized medicine.
- Officers of genomic and proteomic companies interested in diagnostic
technologies.
- Research scientists involved in application of molecular diagnostic
technologies.
- Planners of healthcare services.
Summary
This report describes and evaluates the molecular diagnostics technologies
that will play an important role in practice of medicine, public health,
pharmaceutical industry, forensics and biological warfare in the 21st century.
This includes several polymerase chain reaction (PCR)-based technologies,
fluorescent in situ hybridization (FISH), peptide nucleic acids (PNA),
electrochemical detection of DNA, biochips, nanotechnology and proteomic
technologies.
Initial applications of molecular diagnostics were mostly for infections but
are now increasing in the areas of genetic disorders, preimplantation
screening and cancer. Genetic screening tests, despite some restrictions is a
promising area for future expansion of in vitro diagnostic market. Molecular
diagnostics is being combined with therapeutics and forms an important
component of integrated healthcare. Molecular diagnostic technologies are also
involved in development of personalized medicine based on pharmacogenetics and
pharmacogenomics. Currently, there has been a considerable interest in
developing rapid diagnostic methods for for point-of-care and biowarfare
agents such as anthrax.
The number of companies involved in molecular diagnostics has increased
remarkably during the past few years. More than 500 companies have been
identified to be involved in developing molecular diagnostics and 283 of these
are profiled in the report along with tabulation of 623 collaborations.
Despite the strict regulation, most of the development in molecular
diagnostics has taken place in the United States, which has the largest number
of companies.
The markets for molecular diagnostics technologies are difficult to estimate.
Molecular diagnostics markets overlap with markets for non-molecular
diagnostic technologies in the in vitro diagnostic market and are less well
defined than those for pharmaceuticals. Molecular diagnostic markets are
analyzed for 2008 according to technologies, applications and geographical
regions. Forecasts are made up to 2018. A major portion of the molecular
diagnostic market can be attributed to advances in genomics and proteomics.
Biochip and nanobiotechnology are expected to make a significant contribution
to the growth of molecular diagnostics.
This report was first published as DNA Diagnostics in 1995 by PJB
Publications, UK. It was updated in 1997 as Molecular Diagnostics and the next
edition, Molecular Diagnostics II, was published by Decision Resources Inc in
1999. All the three versions of the reports were well accepted and sold
widely.The report has been rewritten several times since then.
| 
View Cart
